References
1. Covid C, Team R, Covid C, Team R, COVID C, Team R, et al. Coronavirus disease 2019 in children—United States, february 12–april 2, 2020. Morb Mortal Wkly Rep2020 ;69:422.
2. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020. Eurosurveillance 2020 ;25:2000062.
3. Ashour HM, Elkhatib WF, Rahman M, Elshabrawy HA. Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks. Pathogens. 2020 ;9:186.
4. Lotfi B, Farshid S, Dadashzadeh N, Valizadeh R, Rahimi MM. Is coronavirus disease 2019 (COVID-19) associated with renal involvement? A review of century infection. Jundishapur J Microbiol2020 ;13:1-6.
5. Rahimi MM, Jahantabi E, Lotfi B, Forouzesh M, Valizadeh R, Farshid S. Renal and liver injury following the treatment of COVID-19 by remdesivir. J Nephropathol 2021 ;10:1-4.
6. Besharat S, Alamda NM, Dadashzadeh N, Talaie R, Mousavi SS, Barzegar A, et al. Clinical and demographic characteristics of patients with covid-19 who died in modarres hospital. Open Access Maced J Med Sci2020 ;8:144-9.
7. Tabatabaii SA, Soltani P, Khanbabaee G, Sharma D, Valizadeh R, Farahbakhsh N, et al. Sars coronavirus 2, severe acute respiratory syndrome, and middle east respiratory syndrome in children: A review on epidemiology, clinical presentation, and diagnosis. Arch Pediatr Infect Dis 2020 ;8:1-8.
8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet2020 ;395:497-506.
9. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis2020 ;20:773.
10. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020 ;63:364-74.
11. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med2020 ;8:420-2.
12. Meo S, Alhowikan A, Al-Khlaiwi T, Meo I, Halepoto D, Iqbal M, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci 2020 ; 24:2012-9.
13. Martin JB, Jimenez JL, Munoz-Fernandez A. Pentoxifylline and severe acute respiratory syndrome (SARS): a drug to be considered. Med Sci Monit 2003 ;9:SR29-SR34.
14. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet2003 ;361:1773-8.
15. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020 ;8:e21.
16. Gorbalenya AE, Baker SC, Baric R, Groot RJd, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses–a statement of the Coronavirus Study Group. 2020.
17. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). Statpearls [internet]. 2022 .
18. Barzegar A, Ghadipasha M, Rezaei N, Forouzesh M, Valizadeh R. New hope for treatment of respiratory involvement following COVID-19 by bromhexine. Pharmacol Ther2014 ;28:98-108.
19. Brie D, Sahebkar A, Penson PE, Dinca M, Ursoniu S, Serban M-C, et al. Effects of pentoxifylline on inflammatory markers and blood pressure: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 2016 ;34:2318-29.
20. Torres-Alvarez B, Castanedo-Cazares JP, Moncada B. Pentoxifylline in the treatment of actinic prurigo. Dermatology 2004 ;208:198-201.
21. Choonhakarn C, Chaowattanapanit S. Lipodermatosclerosis: Improvement noted with hydroxychloroquine and pentoxifylline. J Am Acad Dermatol2012 ;66:1013-4.
22. Berman B, Wietzerbin J, Sanceau J, Merlin G, Duncan MR. Pentoxifylline inhibits certain constitutive and tumor necrosis factor-α-induced activities of human normal dermal fibroblasts. J Invest Dermatol1992 ;98:706-12.
23. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex. J Med Virol2020 ;92:2050-4.
24. Wray S, Arrowsmith S. The Physiological Mechanisms of the Sex-Based Difference in Outcomes of COVID19 Infection. Front Physiol2021 ;12:627260.
25. Feily A, Daneshpay K, Alighadr A. COVID-19: Pentoxifylline as a potential adjuvant treatment. Int J Clin Pharmacol Ther2020 ;58:406-7.
26. Gonzalez-Pacheco H, Amezcua-Guerra LM, Sandoval J, Arias-Mendoza A. Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2. Eur Rev Med Pharmacol Sci 2020 ;24:7494-6.
27. Hendry BM, Stafford N, Arnold AD, Sangwaiya A, Manglam V, Rosen SD, et al. Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients. Pharmacol Res Perspect2020 ;8:e00631.
28. Maldonado V, Hernandez-Ramirez C, Oliva-Perez EA, Sanchez-Martinez CO, Pimentel-Gonzalez JF, Molina-Sanchez JR, et al. Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study. Int Immunopharmacol2021 ;90:107209.
29. Frampton JE, Brogden RN. Pentoxifylline (Oxpentifylline). Drugs Aging. 1995 ;7:480-503.
30. Frost ML, Treadwell P. Treatment of sickle cell leg ulcers with pentoxifylline. Int J Dermatol 1990 ;29:375-6.
31. Feret W, Nalewajska M, Wojczynski L, Witkiewicz W, Klos P, Dziedziejko V, et al. Pentoxifylline as a Potential Adjuvant Therapy for COVID-19: Impeding the Burden of the Cytokine Storm. J Clin Med2021 ;10.
32. Ghasemnejad-Berenji M, Pashapour S, Sadeghpour S. Pentoxifylline: A Drug with Antiviral and Anti-Inflammatory Effects to Be Considered in the Treatment of Coronavirus Disease 2019. Med Princ Pract2021 ;30:98-100.
33. Seirafianpour F, Mozafarpoor S, Fattahi N, Sadeghzadeh-Bazargan A, Hanifiha M, Goodarzi A. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy? Dermatol Ther2020 ;33:e13733.
34. Monji F, Al-Mahmood Siddiquee A, Hashemian F. Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic. Eur J Pharmacol2020 ;887:173561.
35. Collado-Chagoya R, Hernandez-Chavero H, Ordinola Navarro A, Castillo-Castillo D, Quiroz-Melendez JG, Gonzalez-Veyrand E, et al. CT findings in survivors and non-survivors of COVID-19 and clinical usefulness of a CT scoring system. Radiologia (Engl Ed)2022 ;64:11-6.
36. Kurzeder L, Jorres RA, Unterweger T, Essmann J, Alter P, Kahnert K, et al. A simple risk score for mortality including the PCR Ct value upon admission in patients hospitalized due to COVID-19. Infection.2022 .
37. Boehme AK, Doyle K, Thakur KT, Roh D, Park S, Agarwal S, et al. Disorders of Consciousness in Hospitalized Patients with COVID-19: The Role of the Systemic Inflammatory Response Syndrome. Neurocrit Care2022 ;36:89-96.
38. Galiero R, Pafundi PC, Simeon V, Rinaldi L, Perrella A, Vetrano E, et al. Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study. PLOS ONE2020 ;15:e0243700.
39. Tian ML, Shen Y, Sun ZL, Zha Y. Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis. Int Urol Nephrol 2015 ;47:815-22.
40. Schüller SS, Kempf K, Unterasinger L, Strunk T, Berger A. Intravenous pentoxifylline is well tolerated in critically ill preterm infants with sepsis or necrotizing enterocolitis. Eur J Pediatr2020 ;179:1325-30.
41. Sun S-Y, Li Y, Gao Y-Y, Ran X-W. Efficacy and Safety of Pentoxifylline for Venous Leg Ulcers: An Updated Meta-Analysis. Int J Low Extrem Wounds2021 ;15347346211050769.
42. Dadashzadeh N, Farshid S, Valizadeh R, Nanbakhsh M, Mohammad Rahimi M. Acute respiratory distress syndrome in COVID-19. Immunopathol Persa.2020 ;6:e16.
43. Daneshfar M, Dadashzadeh N, Ahmadpour M, Ragati Haghi H, Rahmani V, Frouzesh M, et al. Lessons of mortality following COVID-19 epidemic in the United States especially in the geriatrics. J Nephropharmacol.2021 ;10:e06.
44. Besharat S AN, Dadashzadeh N, Talaie R, Mousavi SS, Barzegar A, Tavana S, et al. Clinical and demographic characteristics of patients with COVID-19 who died in Modarres hospital. Open Access Maced J Med Sci. 2020 ;8:144-9.
45. Ghiasi N, Valizadeh R, Arabsorkhi M, Hoseyni TS, Esfandiari K, Sadighpour T, et al. Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion. Immunopathol Persa. 2021 ;7:e31.